Spero Therapeutics (SPRO) Market Capitalization (2017 - 2026)

Spero Therapeutics (SPRO) has reported Market Capitalization for 10 consecutive years, with $128.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 21.14% year-over-year to $128.5 million; the trailing twelve-month figure through Jun 2026 stood at $128.5 million (down 21.14% YoY), and the FY2025 full-year result was $131.4 million, up 133.76% from the prior year.
• Market Capitalization retreated to $128.5 million in Q2 2026 per SPRO's latest filing, from $135.5 million in the prior quarter.
• Across five years, Market Capitalization topped out at $285.0 million in Q1 2022 and bottomed at $26.0 million in Q2 2022.
• Historically, Market Capitalization has averaged $97.4 million across 5 years, with a median of $77.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Market Capitalization plunged 93.73% in 2022, then soared 236.57% in 2026.
• Over 5 years, Market Capitalization stood at $65.0 million in 2022, then increased by 19.82% to $77.9 million in 2023, then decreased by 27.82% to $56.2 million in 2024, then soared by 133.76% to $131.4 million in 2025, then slipped by 2.24% to $128.5 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $128.5 million, $135.5 million, and $131.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.